Preventing disease progression in multiple sclerosis-insights from large real-world cohorts

Sinah Engel; Frauke Zipp

doi:10.1186/s13073-022-01044-8

Preventing disease progression in multiple sclerosis-insights from large real-world cohorts

Genome Med. 2022 Apr 20;14(1):41. doi: 10.1186/s13073-022-01044-8.

Authors

Sinah Engel¹, Frauke Zipp²

Affiliations

¹ Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany. sinah.engel@unimedizin-mainz.de.
² Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.

Abstract

Multiple sclerosis is a chronic neuroinflammatory disease with a highly heterogeneous disease course. Preventing lasting disability requires early identification of persons at risk and novel approaches towards patient stratification for personalized treatment decisions. In this comment, we discuss the importance of large datasets of real-world cohorts in order to address this unmet need.

Keywords: Biomarkers, Multi-omics, Patient stratification, Personalized treatment.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Disease Progression
Humans
Multiple Sclerosis* / genetics